Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor
AMES, Iowa, April 24, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the United States Patent & Trademark Office (USPTO) has allowed broad claims to oral pharmaceutical compositions comprising 1-methyl-D-tryptophan (D-1MT) (US Serial No.
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance From the Japan Patent Office for New Patent Broadly Covering Its HyperAcute(R) Cancer Immunotherapy Products
AMES, Iowa, April 17, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the Japan Patent Office has issued a notice of allowance for a patent entitled "Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase," which
View HTML
Toggle Summary NewLink Genetics and Its CEO Are Recognized as High-Tech Leaders by the Technology Association of Iowa
AMES, Iowa, April 13, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that NewLink and its Chief Executive Officer, Dr. Charles Link, each received one of the 2012 Prometheus Awards granted each year by the Technology Association of Iowa.
View HTML
Toggle Summary NewLink Genetics to Present Data at the American Society of Clinical Oncology and Digestive Disease Week Annual Meetings
AMES, Iowa, April 11, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from its HyperAcute® Pancreas immunotherapy and its HyperAcute® Lung immunotherapy as well as its D-1MT IDO pathway inhibitor will be presented at the upcoming American Society of
View HTML
Toggle Summary NewLink Genetics Corporation Reports Fourth Quarter and Full-Year 2011 Financial Results
Conference Call Scheduled for 5:00 pm EDT March 29, 2012
View HTML
Toggle Summary NewLink Enters Into an Agreement Converting Its $6 Million Forgivable Loan to a Royalty Interest
AMES, Iowa, March 27, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it has entered into an agreement with the Iowa Economic Development Authority ("IEDA"). After reviewing NewLink's accomplishments on its milestones and its significant contributions to the State of
View HTML
Toggle Summary NewLink Genetics Announces 2011 Fourth Quarter and Year-End Conference Call and Webcast
AMES, Iowa, March 15, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that financial results for the company's fourth quarter and year ended December 31, 2011 will be released after the market closes on Thursday, March 29, 2012.
View HTML
Toggle Summary NewLink CEO to Participate in Panel Entitled "The Future of Immunotherapy; Key Phase III Trials to Watch"
AMES, Iowa, Feb. 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and CEO, will participate in a panel discussion at the 2012 RBC Capital Markets Global Healthcare Conference on Wednesday, February 29, 2012 at 11 a.m.
View HTML
Toggle Summary NewLink Genetics Corporation Announces Pricing for Initial Public Offering
NewLink Genetics Corporation Announces Pricing for Initial Public Offering AMES, Iowa, Nov. 11, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today the initial public offering of 6,200,000 shares of its common stock at a price of $7.00 per share.
View HTML
Toggle Summary NewLink Announces Board Member Appointment
NewLink Announces Board Member Appointment AMES, Iowa, Oct. 7, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation, a privately held biopharmaceutical company, today announces that Mr. Paul R. Edick was appointed as a director of NewLink Genetics Corporation. Mr.
View HTML